Combining FAK inhibitors with standard cancer treatments has been shown to significantly enhance treatment efficacy and decrease chemotherapy resistance [12, 170], as FAK inhibition sensitizes cancer cells to chemotherapy, leading to better therapeutic outcomes. This evidence concerns the gene PTK2 and cancer.